GlassScriptPhysician profile
Matthew S Roh
NPI 1871807818
$1,975.93
in general payments reported to CMS, 2019-2025
23 companies · $29.26 in 2025
The $29.26 reported for 2025 was less than what a typical Physical Medicine & Rehabilitation provider received nationally (typical 2025 total: $138).
See the full distribution for Physical Medicine & Rehabilitation
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $712 · 2020: $518 · 2021: $171 · 2022: $240 · 2023: $260 · 2024: $45.79 · 2025: $29.26.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $335.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $335.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $368.27 | 2019-2023 | Proclaim |
| Collegium Pharmaceutical, INC. | $192.69 | 2019-2023 | Xtampza, Belbuca |
| Boston Scientific Corporation | $191.39 | 2019-2023 | Wavewriter Alpha Prime 16 |
| Allergan, INC. | $166.70 | 2019-2021 | |
| Scilex Pharmaceuticals INC. | $128.48 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $110.05 | 2019-2022 | |
| Mdd US Operations, LLC | $108.00 | 2019 | |
| Si-Bone, INC. | $105.35 | 2020-2022 | |
| Biodelivery Sciences International, INC. | $88.95 | 2019-2020 | |
| Djo, LLC | $82.61 | 2023 | Aircast, Procare, Donjoy |
| Pfizer INC. | $72.00 | 2019 | |
| Abbvie INC. | $55.35 | 2023 | Botox |
| Indivior INC. | $55.24 | 2019-2020 | |
| Sentynl Therapeutics, INC. | $48.22 | 2019 | |
| Ermi LLC | $31.08 | 2019-2020 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic USA, INC. | $29.99 | 2019 | |
| Electronic Waveform Lab, INC. | $29.26 | 2025 | |
| Depuy Synthes Sales INC. | $27.63 | 2024 | Orthovisc |
| Nevro Corp. | $22.82 | 2019 | |
| Protega Pharmaceutials INC | $18.16 | 2024 | Roxybond |
| Kaleo, INC. | $17.81 | 2019 | |
| Orexo US, INC. | $14.34 | 2020 | |
| Redhill Biopharma INC. | $11.54 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Roh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.